Published in Melanoma Res on December 01, 2007
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res (2009) 1.06
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer (2010) 0.98
Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron (2008) 0.97
Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise. Dermatoendocrinol (2011) 0.90
Clinical Use of PPARgamma Ligands in Cancer. PPAR Res (2008) 0.84
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia. Cancer Microenviron (2015) 0.84
The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Res (2008) 0.81
Principles of modular tumor therapy. Cancer Microenviron (2009) 0.78
Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial. J Eur Acad Dermatol Venereol (2015) 0.76
Current achievements and future perspectives of metronomic chemotherapy. Invest New Drugs (2016) 0.75
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci (2000) 3.70
MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity (2000) 2.93
Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res (2009) 2.87
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood (2004) 2.76
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol (2006) 2.70
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 2.64
Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood (2006) 2.57
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol (2013) 2.31
Foreign body granulomas caused by polymethylmethacrylate microspheres: successful treatment with allopurinol. Arch Dermatol (2003) 2.23
Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res (2006) 2.22
Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (2009) 2.22
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol (1998) 2.09
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet (2012) 2.03
Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol (2010) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res (2004) 1.92
Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function. Microsc Res Tech (1998) 1.86
T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest (2000) 1.85
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol (2000) 1.82
Treatment of oral lichen planus with the 308-nm UVB excimer laser--early preliminary results in eight patients. Lasers Surg Med (2003) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Amoeboid leukocyte crawling through extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J Leukoc Biol (2001) 1.78
Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol (2006) 1.77
A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol (1985) 1.76
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 1.76
Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol (1994) 1.73
Unique brown star shape on dermatoscopy of generalized Dowling-Degos disease. Australas J Dermatol (2011) 1.71
Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res (2000) 1.67
Tattoo pigments are cleaved by laser light-the chemical analysis in vitro provide evidence for hazardous compounds. Photochem Photobiol (2004) 1.66
Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res (2005) 1.65
Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol (2008) 1.65
General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res (2010) 1.64
KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol (2011) 1.59
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2005) 1.58
Tattooing of skin results in transportation and light-induced decomposition of tattoo pigments--a first quantification in vivo using a mouse model. Exp Dermatol (2009) 1.55
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer (1994) 1.53
Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol (2011) 1.51
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood (2004) 1.49
Seborrheic keratosis. J Dtsch Dermatol Ges (2008) 1.49
Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood (2003) 1.47
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood (2006) 1.45
Should elective lymph node dissection be used for treatment of primary melanoma? J Cancer Res Clin Oncol (1989) 1.44
Granulomatous jellyfish dermatitis. J Dtsch Dermatol Ges (2007) 1.43
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Recent advances in betalain research. Phytochemistry (2003) 1.41
Dysplastic melanocytic nevi of the lower leg: sex- and site-specific histopathology. Am J Dermatopathol (2010) 1.40
Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood (2004) 1.40
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
Intense pulsed light (IPL): a review. Lasers Surg Med (2010) 1.39
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem (2003) 1.39
[Smoking -- effects on the skin]. J Dtsch Dermatol Ges (2003) 1.38
Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37
Gene expression profiling of melanocytes following Q-Switched Ruby laser irradiation. Dermatology (2008) 1.37
Dead Sea treatment - principle for outpatient use in atopic dermatitis: safety and efficacy of synchronous balneophototherapy using narrowband UVB and bathing in Dead Sea salt solution. Eur J Dermatol (2002) 1.37
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. Blood (2012) 1.36
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol (2003) 1.36
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 1.35
Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell (1999) 1.33
Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant (2006) 1.32
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol (2000) 1.32
Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol (2010) 1.31
Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control (2010) 1.28
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27